Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C200549> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- NCIT_C200549 IAO_0000115 "A conditionally-activatable tetravalent bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. LB101 contains two anti-CD47 domains blocked by two anti-PD-L1 domains, with human immunoglobulin (Ig) G-derived hinges linking the anti-CD47 and anti-PD-L1 domains. Upon administration of anti-PD-L1/anti-CD47 bispecific monoclonal antibody LB101, the PD-L1 targeting domains target and bind to PD-L1 expressed on tumor cells. The IgG-derived hinges are naturally degraded in the tumor microenvironment (TME) and, upon cleavage, unblock the CD47 domains. The CD47 domains target and bind to CD47, thereby blocking the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and induces antibody-dependent cellular phagocytosis (ADCP). The binding of LB101 to PD-L1 blocks its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation, which protects cancer cells from phagocytosis and allows cancer cells to proliferate. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. By co-targeting CD47 and PD-L1 and activating the CD47 domains within the TME, LB101 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs)." @default.
- NCIT_C200549 NCIT_NHC0 "C200549" @default.
- NCIT_C200549 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C200549 NCIT_P108 "Anti-PD-L1/Anti-CD47 Bispecific Monoclonal Antibody LB101" @default.
- NCIT_C200549 NCIT_P322 "GDC" @default.
- NCIT_C200549 NCIT_P399 "812924" @default.
- NCIT_C200549 NCIT_R124 NCIT_C17710 @default.
- NCIT_C200549 NCIT_R124 NCIT_C17828 @default.
- NCIT_C200549 NCIT_R124 NCIT_C18219 @default.
- NCIT_C200549 NCIT_R124 NCIT_C19986 @default.
- NCIT_C200549 NCIT_R124 NCIT_C40474 @default.
- NCIT_C200549 normalizedInformationContent "100" @default.
- NCIT_C200549 referenceCount "1" @default.
- NCIT_C200549 hasExactSynonym "Anti-CD47/Anti-PD-L1 Bispecific Antibody LB101" @default.
- NCIT_C200549 hasExactSynonym "Anti-PD-L1/Anti-CD47 Bispecific Antibody LB101" @default.
- NCIT_C200549 hasExactSynonym "Anti-PD-L1/Anti-CD47 Bispecific Monoclonal Antibody LB101" @default.
- NCIT_C200549 hasExactSynonym "Anti-PD-L1/CD47 Bispecific Antibody LB101" @default.
- NCIT_C200549 hasExactSynonym "Anti-PDL1/CD47 Bispecific Monoclonal Antibody LB101" @default.
- NCIT_C200549 hasExactSynonym "LB 101" @default.
- NCIT_C200549 hasExactSynonym "LB-101" @default.
- NCIT_C200549 hasExactSynonym "LB101" @default.
- NCIT_C200549 hasExactSynonym "PD-L1 x CD47 Bispecific Antibody LB101" @default.
- NCIT_C200549 hasExactSynonym "PD-L1xCD47 LockBody Bispecific Monoclonal Antibody LB101" @default.
- NCIT_C200549 inSubset NCIT_C157711 @default.
- NCIT_C200549 inSubset NCIT_C157712 @default.
- NCIT_C200549 inSubset NCIT_C176424 @default.
- NCIT_C200549 type Class @default.
- NCIT_C200549 isDefinedBy ncit.owl @default.
- NCIT_C200549 label "Anti-PD-L1/Anti-CD47 Bispecific Monoclonal Antibody LB101" @default.
- NCIT_C200549 subClassOf NCIT_C128057 @default.
- NCIT_C200549 subClassOf NCIT_C129821 @default.
- NCIT_C200549 subClassOf NCIT_C129822 @default.
- NCIT_C200549 subClassOf NCIT_C141144 @default.
- NCIT_C200549 subClassOf NCIT_C143250 @default.
- NCIT_C200549 subClassOf NCIT_C1454 @default.
- NCIT_C200549 subClassOf NCIT_C156893 @default.
- NCIT_C200549 subClassOf NCIT_C159583 @default.
- NCIT_C200549 subClassOf NCIT_C163758 @default.
- NCIT_C200549 subClassOf NCIT_C1908 @default.
- NCIT_C200549 subClassOf NCIT_C1909 @default.
- NCIT_C200549 subClassOf NCIT_C191689 @default.
- NCIT_C200549 subClassOf NCIT_C192655 @default.
- NCIT_C200549 subClassOf NCIT_C200549 @default.
- NCIT_C200549 subClassOf NCIT_C20401 @default.
- NCIT_C200549 subClassOf NCIT_C274 @default.
- NCIT_C200549 subClassOf NCIT_C307 @default.
- NCIT_C200549 subClassOf NCIT_C308 @default.